Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SCHMIDT, R. T.
Right arrow Articles by SPEHLMANN, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SCHMIDT, R. T.
Right arrow Articles by SPEHLMANN, R.
NEUROLOGY 1975;25:622
© 1975 American Academy of Neurology

A pharmacologic study of the stiff-man syndrome

Correlation of clinical symptoms with urinary 3-methoxy-4-hydroxy-phenyl glycol excretion

ROBERT T. SCHMIDT, M.D., STEPHEN M. STAHL, M.D. and RAINER SPEHLMANN, M.D.

Department of Neurology, Northwestern University Medical School, and the Neurology Service, Veterans Administration Research Hospital, Chicago.

We have investigated hypotheses that link the stiff-man syndrome to an imbalance of neurotransmitter systems. No evidence was found to support the concept of defective synaptic transmission at either cholinergic input to Renshaw inhibitory elements or at glycinergic inhibitory input to motoneurons from spinal interneurons, since neither physostigmine nor glycine altered symptomatology. Urinary excretion of the norepinephrine metabolite 3-methoxy-4-hydroxy-phenyl glycol showed a high correlation with clinical status. This suggests the involvement in the stiff-man syndrome of a central norepinephrine neuronal system that has net excitatory effects upon motoneurons, a system whose activity can be increased slightly by levodopa and decreased markedly by diazepam, with corresponding changes in stiffness.

This study was supported in part by National Institute of General Medical Sciences medical scientist research fellowship award GM56040 to Dr. Stahl.

This paper was read at the twenty-seventh annual meeting of the American Academy of Neurology, Miami, May 1975.

Received for publication November 18, 1974.

Reprint requests should be addressed to Dr. Spehlmann at Veterans Administration Research Hospital, 333 East Huron Street, Chicago, IL 60611. Dr. Schmidt's present address is Department of Pathology, Boston City Hospital, Boston, MA. Dr. Stahl's present address is Departments of Pharmacological and Physiological Sciences and Psychiatry, University of Chicago, Chicago, IL.




This article has been cited by other articles:


Home page
Arch NeurolHome page
E. Maida, T. Reisner, K. Summer, and H. Sandor-Eggerth
Stiff-Man Syndrome With Abnormalities in CSF and Computerized Tomography Findings: Report of a Case
Arch Neurol, March 1, 1980; 37(3): 182 - 183.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1975 by AAN Enterprises, Inc.